{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T13:53:00Z","timestamp":1789912380123,"version":"4.0.1"},"reference-count":210,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2003,10]]},"DOI":"10.1586\/14737140.3.5.595","type":"journal-article","created":{"date-parts":[[2005,1,13]],"date-time":"2005-01-13T08:01:44Z","timestamp":1105603304000},"page":"595-614","source":"Crossref","is-referenced-by-count":101,"title":["Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: growth factor and Ras signaling pathways"],"prefix":"10.1586","volume":"3","author":[{"given":"Herbert B","family":"Newton","sequence":"first","affiliation":[{"name":"Dardinger Neuro-Oncology Center, Department of Neurology, Ohio State University Hospitals, 465 Means Hall, 1654 Upham Drive, Columbus, Ohio 43210, USA. newton.12@osu.edu"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2014,1,10]]},"reference":[{"key":"e_1_2_1_5_1","unstructured":"Newton HB. Primary brain tumors: review of etiology diagnosis and treatment. Am. Fain. Physician 49 787\u2013797 (1994)."},{"key":"e_1_2_1_6_1","unstructured":"\u2022Detailed clinical review."},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.1.3.395"},{"key":"e_1_2_1_8_1","first-page":"878","article-title":"Neurological complications of systemic cancer","volume":"59","author":"Newton HB","year":"1999","unstructured":"Newton HB. Neurological complications of systemic cancer. Am Fam. Physician 59, 878\u2013886 (1999).","journal-title":"Am Fam. Physician"},{"key":"e_1_2_1_9_1","unstructured":"\u2022Reviews the neurological complications of cancer including metastatic brain tumors."},{"key":"e_1_2_1_10_1","first-page":"941","article-title":"Management of brain metastases","volume":"13","author":"Wen PY","year":"1999","unstructured":"Wen PY, Loeffler JS. Management of brain metastases. Oncology13, 941\u2013961 (1999).","journal-title":"Oncology"},{"key":"e_1_2_1_11_1","unstructured":"\u2022\u2022Thorough review."},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.18353"},{"key":"e_1_2_1_13_1","unstructured":"\u2022\u2022Thorough review of primary brain tumorpharmacotherapy."},{"key":"e_1_2_1_14_1","first-page":"2585","article-title":"Canellos GP","volume":"71","author":"Fine HA","year":"1993","unstructured":"Fine HA, Dear KBG, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer71, 2585\u20132597 (1993).","journal-title":"Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer"},{"key":"e_1_2_1_15_1","unstructured":"\u2022\u2022 Meta-analysis demonstrates survival advantage for chemotherapy."},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.2.5.495"},{"key":"e_1_2_1_17_1","unstructured":"\u2022Thorough review."},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.3109\/07357909109084641"},{"key":"e_1_2_1_19_1","first-page":"328","article-title":"Wiestler OD","volume":"15","author":"von Deimling A","year":"1995","unstructured":"von Deimling A, Louis DN, Wiestler OD. Molecular pathways in the formation of gliomas. Gila 15,328\u2013338 (1995).","journal-title":"Molecular pathways in the formation of gliomas. Gila"},{"key":"e_1_2_1_20_1","first-page":"27","article-title":"SW Genetics of adult malignant gliomas","volume":"14","author":"Shapiro JR","year":"1998","unstructured":"Shapiro JR, Coons SW Genetics of adult malignant gliomas. BNI Q. 14,27\u201342 (1998).","journal-title":"BNI Q"},{"key":"e_1_2_1_21_1","unstructured":"\u2022Thorough review."},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.891601"},{"key":"e_1_2_1_23_1","unstructured":"\u2022\u2022Thorough review of molecular biologyand signal transduction."},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1659742"},{"key":"e_1_2_1_25_1","doi-asserted-by":"crossref","unstructured":"Cantley LC Auger KR Carpenter C et al. Oncogenes and signal transduction. Cell. 64 281\u2013302 (1991).","DOI":"10.1016\/0092-8674(91)90639-G"},{"key":"e_1_2_1_26_1","unstructured":"\u2022Early review of growth factors as oncogenes."},{"key":"e_1_2_1_27_1","first-page":"168","article-title":"Stiles CD","volume":"60","author":"Guha A","year":"1995","unstructured":"Guha A, Dashner K, Black PM, Wagner JA, Stiles CD. Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int.j Cancer 60, 168\u2013173 (1995).","journal-title":"Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int.j Cancer"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M101056200"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/35074593"},{"key":"e_1_2_1_30_1","unstructured":"Lokker NA Sullivan CM Hollenbach SJ Israel MA Giese NA. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res. 62 1729\u20131735 (2002)."},{"key":"e_1_2_1_31_1","doi-asserted-by":"crossref","unstructured":"Westermark B Heldin CH Nister M. Platelet-derived growth factor in human glioma. Clia 15 257-263 (1995). \u2022\u2022 Thorough review.","DOI":"10.1002\/glia.440150307"},{"key":"e_1_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)31591-6"},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.69.1.373"},{"key":"e_1_2_1_34_1","unstructured":"\u2022 Thorough review."},{"key":"e_1_2_1_35_1","first-page":"309","article-title":"Dubois-Dalcq M","volume":"1153","author":"Richardson WD","year":"1988","unstructured":"Richardson WD, Pringle N, Mosley MJ, Westermark B, Dubois-Dalcq M. A role for platelet-derived growth factor in normal gliogenesis in the central nervous system. Ce1153, 309\u2013319 (1988).","journal-title":"A role for platelet-derived growth factor in normal gliogenesis in the central nervous system. Ce"},{"key":"e_1_2_1_36_1","first-page":"3213","article-title":"Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops","volume":"52","author":"Hermanson M","year":"1992","unstructured":"Hermanson M, Funa K, Hartman M et al Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res. 52,3213\u20133219 (1992).","journal-title":"Cancer Res"},{"key":"e_1_2_1_37_1","unstructured":"\u2022Detailed study of platelet-derived growth factor (PDGF) autocrine and paracrine loops."},{"key":"e_1_2_1_38_1","first-page":"4550","article-title":"Clark WC et al Amplification and\/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors","volume":"52","author":"Fleming TP","year":"1992","unstructured":"Fleming TP, Saxena A, Clark WC et al Amplification and\/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res. 52, 4550\u20134553 (1992).","journal-title":"Cancer Res"},{"key":"e_1_2_1_39_1","doi-asserted-by":"publisher","DOI":"10.1081\/CNV-100107745"},{"key":"e_1_2_1_40_1","unstructured":"\u2022General overview of anibody-mediated therapy. Druker BJ. 5TI571: a paradigm of new agents for cancer therapeutics. J. Clin."},{"key":"e_1_2_1_41_1","unstructured":"C0i 20 325\u2013334 (2001)."},{"key":"e_1_2_1_42_1","unstructured":"\u2022\u2022"},{"key":"e_1_2_1_43_1","unstructured":"\u2022\u2022"},{"key":"e_1_2_1_44_1","unstructured":"Kilic T Alberta JA Zdunek PR eta]."},{"key":"e_1_2_1_45_1","unstructured":"\u2022Clear demonstration that imatinib has activity against glioblastoma multiforrne (GBM)."},{"key":"e_1_2_1_46_1","unstructured":"Wen PY Yung WK Hess K et a\/. Phase I"},{"key":"e_1_2_1_47_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.48.070179.001205"},{"key":"e_1_2_1_48_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.7892601"},{"key":"e_1_2_1_49_1","first-page":"662","article-title":"Inhibitors of protein tyrosine kinases. Curt: Opin","volume":"6","author":"Fry DW","year":"1995","unstructured":"Fry DW, Bridges AJ. Inhibitors of protein tyrosine kinases. Curt: Opin. Biotechnol 6, 662\u2013667 (1995).","journal-title":"Biotechnol"},{"key":"e_1_2_1_50_1","doi-asserted-by":"crossref","unstructured":"Levitzki A. Tyrosine kinases as targets for cancer therapy. Eur. J. Cancer 38\\(Suppl. 5) S11\u2014S18 (2002).","DOI":"10.1016\/S0959-8049(02)80598-6"},{"key":"e_1_2_1_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0093-7754(01)90100-9"},{"key":"e_1_2_1_52_1","first-page":"550","article-title":"Yu JC et al Development of antagonists of the platelet-derived growth factor receptor family","volume":"2","author":"Giese NA","year":"2001","unstructured":"Giese NA, Lokker NA, Yu JC et al Development of antagonists of the platelet-derived growth factor receptor family. Oncol Spectmms2, 550\u2013556 (2001).","journal-title":"Oncol Spectmms"},{"key":"e_1_2_1_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(97)00097-1"},{"key":"e_1_2_1_54_1","doi-asserted-by":"crossref","unstructured":"Maguire MP Sheets KR McVety K Spada AP Zilberstein A. A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J. Med. Chem. 37 2129-2137 (1994).","DOI":"10.1021\/jm00040a003"},{"key":"e_1_2_1_55_1","first-page":"261","article-title":"Bonsert RVV","volume":"55","author":"Spacey GD","year":"1998","unstructured":"Spacey GD, Uings IJ, Slater M, Hirst S, Bonsert RVV. Indolocarbazoles. Potent and selective inhibitors of platelet-derived growth factor receptor autophosphorylation. Biochem. Pharmacol 55,261\u2013271 (1998).","journal-title":"Indolocarbazoles. Potent and selective inhibitors of platelet-derived growth factor receptor autophosphorylation. Biochem. Pharmacol"},{"key":"e_1_2_1_56_1","first-page":"214","article-title":"Inhibitors of growth factor receptor kinase-dependent signaling pathways in anticancer chemotherapy \u2014 clinical progress. Curl: Opin","volume":"5","author":"Renhowe PA","year":"2002","unstructured":"Renhowe PA. Inhibitors of growth factor receptor kinase-dependent signaling pathways in anticancer chemotherapy \u2014 clinical progress. Curl: Opin. Dmg Discov Develop. 5,214\u2013224 (2002).","journal-title":"Dmg Discov Develop"},{"key":"e_1_2_1_57_1","doi-asserted-by":"crossref","unstructured":"Eckhardt SG Rizzo J Sweeney KR et al Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors. J. Clin. Oncol 17 1095\u20131104 (1999).","DOI":"10.1200\/JCO.1999.17.4.1095"},{"key":"e_1_2_1_58_1","unstructured":"Malkin MG Mason WP Lieberman FS Hannah AL. Phase I study of SU101 a novel signal transduction inhibitor in recurrent malignant glioma. Proc. Am. Soc. Clin. Oncol 16 385a (1997)."},{"key":"e_1_2_1_59_1","unstructured":"Malkin MG Rosen L Lopez AM Mulay M Cloughesy T Hannah AL. Phase 2 study of SU101 a PDGFR signal transduction inhibitor in recurrent malignant glioma. Proc. Am. Soc. Clin. Oncol 17 390a (1998)."},{"key":"e_1_2_1_60_1","unstructured":"Shapiro WR Ashby LS Obbens EAMT DePaoli AC Hannah AL. Phase I\/II study of SU101 in combination with carmustine in the treatment of patients newly diagnosed with malignant glioma. Neurooncology 1 S55 (1999)."},{"key":"e_1_2_1_61_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra013339"},{"key":"e_1_2_1_62_1","unstructured":"\u2022\u2022Thorough review of pharrnacotherapeuticsof imatinib mesylate."},{"key":"e_1_2_1_63_1","doi-asserted-by":"crossref","unstructured":"Buchdunger E O'Reilly T Wood J. Pharmacology of imatinib (5TI571). Eur Cancer 38\\(Suppl. 5) S28\u2014S36 (2002).","DOI":"10.1016\/S0959-8049(02)80600-1"},{"key":"e_1_2_1_64_1","doi-asserted-by":"crossref","unstructured":"Manley PW Cowan-Jacob SW Buchdunger E et al. Imatinib: a selective tyrosine kinase inhibitor. Eur J. Cancer 38\\(Suppl. 5) S19\u2014S27 (2002).","DOI":"10.1016\/S0959-8049(02)80599-8"},{"key":"e_1_2_1_65_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.6.1692"},{"key":"e_1_2_1_66_1","doi-asserted-by":"crossref","unstructured":"Brooks BJ Bani JC Fletcher CDM Demeteri GD. Response of metastatic gastrointestinal stromal tumor including CNS involvement to imatinib mesylate (STI-571).j Clin. Oncol 20 870\u2013872 (2002).","DOI":"10.1200\/JCO.2002.20.3.870"},{"key":"e_1_2_1_67_1","doi-asserted-by":"crossref","unstructured":"Hackel PO Zwick E Prenzel N Ullrich A. Epidermal growth factor receptors: critical mediators of multiple receptor pathways Curt: Opin. Cell Biol.184\u2013189 (1999).","DOI":"10.1016\/S0955-0674(99)80024-6"},{"key":"e_1_2_1_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(98)00045-X"},{"key":"e_1_2_1_69_1","unstructured":"\u2022Excellent review of epidermal growth factor receptor (EGFR) structure and function."},{"key":"e_1_2_1_70_1","unstructured":"Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J. Clin. Oncol 19 32S-40S (2001).Thorough review."},{"key":"e_1_2_1_71_1","first-page":"S3\u2014S8","article-title":"EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities","volume":"37","author":"Yarden Y. The","year":"2001","unstructured":"Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur. Cancer 37, S3\u2014S8 (2001).","journal-title":"Eur. Cancer"},{"key":"e_1_2_1_72_1","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1989.70.6.0916"},{"key":"e_1_2_1_73_1","doi-asserted-by":"crossref","unstructured":"Hurtt MR Moossy J Donovan-Peluso M Locker J. Amplification of epidermal growth factor receptor gene in gliomas: histopathology and prognosis. Neumpathol Exp. Neuml 51 84\u201390 (1992).","DOI":"10.1097\/00005072-199201000-00010"},{"key":"e_1_2_1_74_1","first-page":"1383","article-title":"Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas","volume":"60","author":"Frederick L","year":"2000","unstructured":"Frederick L, Wang XY, Eley G, James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res. 60,1383\u20131387 (2000).","journal-title":"Cancer Res"},{"key":"e_1_2_1_75_1","unstructured":"\u2022\u2022Definitive review of EGFR mutationsin GBM."},{"key":"e_1_2_1_76_1","first-page":"2965","article-title":"Bigner SH eta]","volume":"89","author":"Wong AJ","year":"1992","unstructured":"Wong AJ, Ruppert JM, Bigner SH eta].Structural alterations of the epidermal growth factor receptor gene in human gliomas. Pmc. Natl Acad. Sci. 89, 2965\u20132969 (1992).","journal-title":"Structural alterations of the epidermal growth factor receptor gene in human gliomas. Pmc. Natl Acad. Sci"},{"key":"e_1_2_1_77_1","first-page":"2313","article-title":"Hamid ML eta]","volume":"9","author":"Ekstrand AJ","year":"1994","unstructured":"Ekstrand AJ, Longo N, Hamid ML eta]. Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene 9, 2313\u20132320 (1994).","journal-title":"Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene"},{"key":"e_1_2_1_78_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.16.7727"},{"key":"e_1_2_1_79_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00146079"},{"key":"e_1_2_1_80_1","first-page":"141","article-title":"Bhushan A,Tritton TR","volume":"40","author":"Penar PL","year":"1997","unstructured":"Penar PL, Khoshyomn S, Bhushan A,Tritton TR. Inhibition of epidermal growth factor receptor-associated tyrosine kinase blocks glioblastoma invasion of the brain. Neurosurgety40,141\u2013151(1997).","journal-title":"Inhibition of epidermal growth factor receptor-associated tyrosine kinase blocks glioblastoma invasion of the brain. Neurosurgety"},{"key":"e_1_2_1_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(01)01609-1"},{"key":"e_1_2_1_82_1","first-page":"4307","article-title":"Loeffler JS","volume":"62","author":"Chakravarti A","year":"2002","unstructured":"Chakravarti A, Chaldadar A, Delaney MA, Latham DE, Loeffler JS. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a Ras-dependent manner. Cancer Res. 62, 4307\u20134315 (2002).","journal-title":"The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a Ras-dependent manner. Cancer Res"},{"key":"e_1_2_1_83_1","first-page":"3335","article-title":"Martinson HM et alMutant epidermal growth factor receptor upregulates molecular effectors of tumor invasion","volume":"62","author":"Lal A","year":"2002","unstructured":"Lal A, Glazer CA, Martinson HM et alMutant epidermal growth factor receptor upregulates molecular effectors of tumor invasion. Cancer Res. 62,3335\u20133339 (2002).","journal-title":"Cancer Res"},{"key":"e_1_2_1_84_1","doi-asserted-by":"crossref","unstructured":"Nagane M Levitzki A Gazit A Cavanee WK Huang HJS. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc. Natl Acad. Sc]. 95 5724-5729 (1998).","DOI":"10.1073\/pnas.95.10.5724"},{"key":"e_1_2_1_85_1","first-page":"1442","article-title":"Guha A","volume":"45","author":"Feldkamp MM","year":"1999","unstructured":"Feldkamp MM, Lala P, Lau N, Roncari L, Guha A. Expression of activated epidermal growth factor receptors, ras-guanosine triphosphate and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery45, 1442\u20131453 (1999).","journal-title":"Expression of activated epidermal growth factor receptors, ras-guanosine triphosphate and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery"},{"key":"e_1_2_1_86_1","first-page":"553","article-title":"Dickson RB","volume":"9","author":"Ennis BW","year":"1991","unstructured":"Ennis BW, Lippman ME, Dickson RB.The EGF receptor system as a target for antitumor therapy. Cancer Invest. 9, 553\u2013562 (1991).","journal-title":"The EGF receptor system as a target for antitumor therapy. Cancer Invest"},{"key":"e_1_2_1_87_1","unstructured":"Baselga J. New therapeutic agents targeting the epidermal growth factor receptor.Clin. Oncol 18 54S-59S (2000)."},{"key":"e_1_2_1_88_1","unstructured":"Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. Clin. Oncol 20 1S-13S (2002). \u2022\u2022 Thorough review"},{"key":"e_1_2_1_89_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/95.12.851"},{"key":"e_1_2_1_90_1","unstructured":"\u2022\u2022 Thorough review."},{"key":"e_1_2_1_91_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.01.504"},{"key":"e_1_2_1_92_1","unstructured":"\u2022\u2022Thorough review of EGFR biology andtreatment."},{"key":"e_1_2_1_93_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10372"},{"key":"e_1_2_1_94_1","unstructured":"\u2022Excellent overview of antibody therapy for EGFR."},{"key":"e_1_2_1_95_1","first-page":"S16\u2014S22","article-title":"EGFR as a target for anticancer therapy \u2014 focus on cetuximab","volume":"37","author":"Baselga J. The","year":"2001","unstructured":"Baselga J. The EGFR as a target for anticancer therapy \u2014 focus on cetuximab. Eurj Cancer37, S16\u2014S22(2001).","journal-title":"Eurj Cancer"},{"key":"e_1_2_1_96_1","doi-asserted-by":"publisher","DOI":"10.1227\/00006123-200210000-00028"},{"key":"e_1_2_1_97_1","unstructured":"\u2022Cetuximab is active against GBM cells that overexpress EGFR"},{"key":"e_1_2_1_98_1","first-page":"5349","article-title":"Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor","volume":"61","author":"Mishima K","year":"2001","unstructured":"Mishima K, Johns TG, Luwor RB et al.Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res. 61,5349\u20135354 (2001).","journal-title":"Cancer Res"},{"key":"e_1_2_1_99_1","doi-asserted-by":"crossref","unstructured":"Baselga J Rischin D Ranson M et alPhase I safety pharmacokinetic and pharmacodynamic trial of ZD1839 a selective oral epidermal growth factor receptor tyrosine kinase inhibitor in patients with five selected solid tumor types. .1. Clin. Oncol 20 4292\u20134302 (2002).","DOI":"10.1200\/JCO.2002.03.100"},{"key":"e_1_2_1_100_1","doi-asserted-by":"crossref","unstructured":"Herbst RS Maddox AM Rothenberg ML et al Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a Phase I trial. Clin. Oncol 20 3815\u20133825 (2002).","DOI":"10.1200\/JCO.2002.03.038"},{"key":"e_1_2_1_101_1","doi-asserted-by":"crossref","unstructured":"Nakagawa K Tamura T Negoro S et al.Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa ZD1839) in Japanese patients with solid malignant tumors. Ann. Oncol 14 922\u2013930 (2003).","DOI":"10.1093\/annonc\/mdg250"},{"key":"e_1_2_1_102_1","doi-asserted-by":"crossref","unstructured":"Hidalgo M Siu LL Nemunaitis J et al.Phase I and pharmacologic study of OSI-774 an epidermal growth factor receptor tyrosine kinase inhibitor in patients with advanced solid malignancies.Clin. Oncol 19 3267\u20133279 (2001).","DOI":"10.1200\/JCO.2001.19.13.3267"},{"key":"e_1_2_1_103_1","unstructured":"Heimberger AB Learn CA Archer GE et al Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral specific EGFR-tyrosine kinase inhibitor ZD1839 (Iressa). Clin. Cancer Res. 8 3496-3502 (2002)."},{"key":"e_1_2_1_104_1","unstructured":"Guillamo JS Leuraud P de Bouard S et al Antiproliferative and anti-invasive EGFR amplification dependent and anti-angiogenic EGFR amplification independent activity of ZD1839 (Iressa) tyrosine kinase inhibitor on human glioblastomas. Proc. Am. Assoc. Cancer Res. 44 231 (2003)."},{"key":"e_1_2_1_105_1","doi-asserted-by":"crossref","unstructured":"Lieberman FS Cloughesy T Deangelis Let al Phase I\u2014II study of ZD-1839 for recurrent malignant gliomas andmeningiomas progressing after radiation therapy. Proc. Am. Soc. Clin. Oncol 22 105 (2003).","DOI":"10.1200\/jco.2004.22.90140.1510"},{"key":"e_1_2_1_106_1","unstructured":"Peery TS Reardon DA Quinn J et al.Phase II of ZD1839 for patients with first relapse glioblastoma. Proc. Am. Soc. Clin. Oncol 22 99 (2003)."},{"key":"e_1_2_1_107_1","doi-asserted-by":"crossref","unstructured":"Akita RW Sliwkowski MX. Preclinical studies with erlotinib (Tarceva). Semin. Oncol 30\\(Suppl. 7) 15\u201324 (2003).","DOI":"10.1016\/S0093-7754(03)00187-8"},{"key":"e_1_2_1_108_1","doi-asserted-by":"crossref","unstructured":"Hidalgo M Bloedow D. Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of erlotinib (Tarceva). Semin. Oncol 30\\(Suppl. 7) 25\u201333 (2003).","DOI":"10.1016\/S0093-7754(03)00186-6"},{"key":"e_1_2_1_109_1","doi-asserted-by":"crossref","unstructured":"Grunwald V Hidalgo M. Development of the epidermal growth factor receptor inhibitor OSI-774. Semin. \u00b0nevi 30\\(Suppl. 7) 26\u201331 (2003).","DOI":"10.1016\/S0093-7754(03)70022-0"},{"key":"e_1_2_1_110_1","doi-asserted-by":"crossref","unstructured":"Prados M Chang S Burton E et al.Phase I study of OSI-774 alone or with temozolomide in patients with malignant glioma. Proc. Am. Soc. Clin. \u00b0nevi 22 99 (2003).","DOI":"10.1016\/S1359-6349(03)90067-X"},{"key":"e_1_2_1_111_1","first-page":"895","article-title":"Allen MB","volume":"134","author":"Samuels V","year":"1989","unstructured":"Samuels V, Barrett JM, Bockman S, Pantazis CG, Allen MB. Immunocytochemical study of transforming growth factor expression in benign and malignant gliomas. Am. Pathol 134,895\u2013902 (1989).","journal-title":"Immunocytochemical study of transforming growth factor expression in benign and malignant gliomas. Am. Pathol"},{"key":"e_1_2_1_112_1","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1991.75.1.0097"},{"key":"e_1_2_1_113_1","first-page":"5598","article-title":"\u00f6stman A, Nist\u00e9r M, Westermark B","volume":"57","author":"El-Obeid A","year":"1997","unstructured":"El-Obeid A, Bongcam-Rudloff E, S\u00f6rby M, \u00f6stman A, Nist\u00e9r M, Westermark B. Cell scattering and migration induced by autocrine transforming factor a in human glioma cells in vitt-a Cancer Res. 57, 5598\u20135604 (1997).","journal-title":"Cell scattering and migration induced by autocrine transforming factor a in human glioma cells in vitt-a Cancer Res"},{"key":"e_1_2_1_114_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005824802617"},{"key":"e_1_2_1_115_1","unstructured":"\u2022In-depth review of transforming growth factor (TGF)-a and brain tumors."},{"key":"e_1_2_1_116_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.67.1.753"},{"key":"e_1_2_1_117_1","unstructured":"\u2022\u2022Detailed and exhaustive review."},{"key":"e_1_2_1_118_1","doi-asserted-by":"crossref","unstructured":"Blobe GC Schiemann WP Lodish HF.Role of transforming growth factor 13 in human disease. N Engl. I Merl 342 1350\u20131358 (2000).","DOI":"10.1056\/NEJM200005043421807"},{"key":"e_1_2_1_119_1","unstructured":"\u2022\u2022Thorough review of TGF-I3 biology"},{"key":"e_1_2_1_120_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.17.1388"},{"key":"e_1_2_1_121_1","unstructured":"\u2022\u2022Thorough review of TGF-I3 inoncogenesis."},{"key":"e_1_2_1_122_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005863419880"},{"key":"e_1_2_1_123_1","doi-asserted-by":"crossref","unstructured":"Platten M Wick W Weller M. Malignantglioma biology: role for TGF-0 in growth motility angiogenesis and immune escape. Nlicrosc. Res. Tech. 52 401-410 (2001).","DOI":"10.1002\/1097-0029(20010215)52:4<401::AID-JEMT1025>3.0.CO;2-C"},{"key":"e_1_2_1_124_1","unstructured":"\u2022Excellent review of TGF-0 and glioma biology."},{"key":"e_1_2_1_125_1","doi-asserted-by":"crossref","unstructured":"Jennings MT Maciunas RJ Carver R et al.TGF-01 and TGF-02 are potential growth regulators for low-grade and malignant gliomas in vitt-a evidence in support of an autocrine hypothesis. int. J Cancer 49 129\u2013139 (1991).","DOI":"10.1002\/ijc.2910490124"},{"key":"e_1_2_1_126_1","doi-asserted-by":"crossref","unstructured":"Yamada N Kato M Yamashita H et al.Enhanced expression of transforming growth factor-0 and its type-I and type-II receptors in human glioblastomas. int. J Cancer 62 386\u2013392 (1995).","DOI":"10.1002\/ijc.2910620405"},{"key":"e_1_2_1_127_1","doi-asserted-by":"crossref","unstructured":"Kjellman C Olofsson SP Hansson 0 et al.Expression of TGF-0 isoforms TGF-0 receptors and Smad molecules at different stages of human glioma. Int. J Cancer 89 251\u2013258 (2000).","DOI":"10.1002\/1097-0215(20000520)89:3<251::AID-IJC7>3.0.CO;2-5"},{"key":"e_1_2_1_128_1","doi-asserted-by":"crossref","unstructured":"Isoe S Naganuma H Nakano S et al.Resistance to growth inhibition by transforming growth factor-0 in malignant glioma cells with functional receptors. J. Neurosurg. 88 529-534 (1998).","DOI":"10.3171\/jns.1998.88.3.0529"},{"key":"e_1_2_1_129_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005767616500"},{"key":"e_1_2_1_130_1","doi-asserted-by":"crossref","unstructured":"Maxwell M Galanopoulos T Neville-Golden J Antoniades HN. Effect of the expression of transforming growth factor-02 in primary human glioblastomas on immunosuppression and loss of immune surveillance. J. Neurosurg. 79 799-804 (1992).","DOI":"10.3171\/jns.1992.76.5.0799"},{"key":"e_1_2_1_131_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012209518843"},{"key":"e_1_2_1_132_1","doi-asserted-by":"crossref","unstructured":"Liau LM Fakhrai H Black KL. Prolonged survival of rats with intracranial C6 gliomas by treatment with TGF-0 antisense gene. Neural. Res. 20 742-747 (1998).","DOI":"10.1080\/01616412.1998.11740594"},{"key":"e_1_2_1_133_1","unstructured":"Stauder GM Hau P Bogdahn U et al. A TGF-02 specific antisense oligonucleotide (AP12009) as continuous intratumoral treatment of recurrent high-grade glioma patients. A clinical Phase I\/II extension study. Proc. Am. Soc. Gun. Oncol 22 109 (2003)."},{"key":"e_1_2_1_134_1","unstructured":"Hau P Bogdahn U Grauer 0 et al. Intratumoral treatment of high-grade glioma with a TGF-02 antisense oligonucleotide (AP12009): safety and first efficacy data of a clinical Phase I\/II dose escalation study. Proc. Am. Assoc. Cancer Res. 44 1228 (2003)."},{"key":"e_1_2_1_135_1","doi-asserted-by":"publisher","DOI":"10.1016\/0955-2235(89)90012-4"},{"key":"e_1_2_1_136_1","unstructured":"\u2022Detailed review of fibroblast growth factor (FGF) biology."},{"key":"e_1_2_1_137_1","doi-asserted-by":"crossref","unstructured":"Dunn IF Heese 0 Black PM. Growth factors in glioma angiogenesis: FGFs PDGF EGF and TGFs. I Neurooncol 50 121\u2013137 (2000).","DOI":"10.1023\/A:1006436624862"},{"key":"e_1_2_1_138_1","unstructured":"\u2022Detailed review of growth factors and angiogenesis."},{"key":"e_1_2_1_139_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.1991.tb01938.x"},{"key":"e_1_2_1_140_1","first-page":"5760","article-title":"Soi A,Goldblatt SA, Rizkalla WM","volume":"51","author":"Stefanik DF","year":"1991","unstructured":"Stefanik DF, Rizkalla LR, Soi A,Goldblatt SA, Rizkalla WM. Acidic and basic fibroblast growth factors are present in glioblastoma multiforme. Cancer Res. 51, 5760\u20135765 (1991).","journal-title":"Acidic and basic fibroblast growth factors are present in glioblastoma multiforme. Cancer Res"},{"key":"e_1_2_1_141_1","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1992.76.5.0792"},{"key":"e_1_2_1_142_1","doi-asserted-by":"crossref","unstructured":"Brem S Tsanaclis AMC Gately S Gross JL Herblin WF. Immunolocalization of basic fibroblast growth factor to the microvasculature of human brain tumors. Cancer70 2673\u20132680 (1992).in Morrison RS Yamaguchi F Saya H et al. Basic fibroblast growth factor and fibroblast growth factor receptor I are implicated in the growth of human astrocytomas.Neumoncol 18 207\u2013216 (1994).","DOI":"10.1002\/1097-0142(19921201)70:11<2673::AID-CNCR2820701118>3.0.CO;2-F"},{"key":"e_1_2_1_143_1","doi-asserted-by":"crossref","unstructured":"Joy A Moffett J Neary K et al. Nuclear accumulation of FGF-2 is associated with proliferation of human astrocytes and glioma cells. Oncogene 14 171\u2013183 (1997).","DOI":"10.1038\/sj.onc.1200823"},{"key":"e_1_2_1_144_1","first-page":"3061","article-title":"Otani N eta]","volume":"97","author":"Fukui S","year":"2003","unstructured":"Fukui S, Nawashiro H, Otani N eta]. Nuclear accumulation of basic fibroblast growth factor in human astrocytic tumors. A poor prognostic factor. Cancer 97, 3061\u20133067 (2003).","journal-title":"Nuclear accumulation of basic fibroblast growth factor in human astrocytic tumors. A poor prognostic factor. Cancer"},{"key":"e_1_2_1_145_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.2.484"},{"key":"e_1_2_1_146_1","first-page":"4059","article-title":"Induction of apoptosis in glioma cells: an approach to control tumor growth by blocking basic fibroblast growth factor autocrine loop","volume":"20","author":"Fukomoto M","year":"2000","unstructured":"Fukomoto M, Takahashi JA, Murai N, Ueba T, Kono K, Nakatsu S. Induction of apoptosis in glioma cells: an approach to control tumor growth by blocking basic fibroblast growth factor autocrine loop. Anticancer Res. 20,4059\u20134066(2000).","journal-title":"Anticancer Res"},{"key":"e_1_2_1_147_1","first-page":"1717","article-title":"Lemi\u00e8re S eta]","volume":"61","author":"Auguste P","year":"2001","unstructured":"Auguste P, Garsel DB, Lemi\u00e8re S eta]. Inhibition of fibroblast growth factor\/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and independent mechanisms. Cancer Res. 61,1717\u20131726 (2001).","journal-title":"Inhibition of fibroblast growth factor\/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and independent mechanisms. Cancer Res"},{"key":"e_1_2_1_148_1","doi-asserted-by":"crossref","unstructured":"Miyaji K Tani E Nakano A Ikemoto H Kaba K. Inhibition by 5 methylthioadenosine of cell growth and tyrosine kinase activity stimulated by fibroblast growth factor receptor in human gliomas. I Neurosurg. 83 690-697 (1995).","DOI":"10.3171\/jns.1995.83.4.0690"},{"key":"e_1_2_1_149_1","first-page":"955","article-title":"Sun L eta]","volume":"276","author":"Mohammadi M","year":"1997","unstructured":"Mohammadi M, McMahon G, Sun L eta]. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 276, 955\u2013960 (1997).","journal-title":"Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science"},{"key":"e_1_2_1_150_1","first-page":"55","article-title":"Small molecule inhibitors of the platelet-derived growth factor receptor, the fibroblast growth factor receptor and Src family tyrosine kinases","volume":"76","author":"Showalter HDH","year":"1997","unstructured":"Showalter HDH, Kraker AJ. Small molecule inhibitors of the platelet-derived growth factor receptor, the fibroblast growth factor receptor and Src family tyrosine kinases. Pharmacol firer. 76, 55\u201371 (1997).","journal-title":"Pharmacol firer"},{"key":"e_1_2_1_151_1","first-page":"443","article-title":"Rosen N","volume":"9","author":"Cullen KJ","year":"1991","unstructured":"Cullen KJ, Yee D, Rosen N. Insulin-like growth factors in human malignancy. Cancer Invest. 9,443\u2013454 (1991).","journal-title":"Insulin-like growth factors in human malignancy. Cancer Invest"},{"key":"e_1_2_1_152_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199702273360907"},{"key":"e_1_2_1_153_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.18.1472"},{"key":"e_1_2_1_154_1","doi-asserted-by":"crossref","unstructured":"Baskin DG Wilcox BJ Figlewicz DP Coma DM. Insulin and insulin-like growth factors in the CNS. Trends Neuroscill 107\u2013111 (1988).","DOI":"10.1016\/0166-2236(88)90155-5"},{"key":"e_1_2_1_155_1","doi-asserted-by":"publisher","DOI":"10.1227\/00006123-198906000-00001"},{"key":"e_1_2_1_156_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-71-1-199"},{"key":"e_1_2_1_157_1","first-page":"972","article-title":"Hollis R","volume":"74","author":"Glick RP","year":"1991","unstructured":"Glick RP, Unterman TG, Hollis R. Radioimmunoassay of insulin-like growth factors in cyst fluid of central nervous system tumors. J. Neurosurg. 74,972\u2013978 (1991).","journal-title":"Radioimmunoassay of insulin-like growth factors in cyst fluid of central nervous system tumors. J. Neurosurg"},{"key":"e_1_2_1_158_1","first-page":"2475","article-title":"V Characterization of insulin-like growth factor 1 in human primary brain tumors","volume":"53","author":"Sandberg-Nordqvist AC","year":"1993","unstructured":"Sandberg-Nordqvist AC, Sthalbom PA, Reinecke M, Colllins VP, Hoist HV, Sara V Characterization of insulin-like growth factor 1 in human primary brain tumors. Cancer Res. 53,2475\u20132478 (1993).","journal-title":"Cancer Res"},{"key":"e_1_2_1_159_1","doi-asserted-by":"crossref","unstructured":"Glick RP Unterman TG Van Der Woude M Blaydes LZ. Insulin and insulin-like growth factors in central nervous system tumors. Part V: production of insulin-like growth factors land II in vitro. j Neumswg. 77 445\u2013450 (1992).","DOI":"10.3171\/jns.1992.77.3.0445"},{"key":"e_1_2_1_160_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204532"},{"key":"e_1_2_1_161_1","first-page":"1822","article-title":"Lassak A eta]","volume":"8","author":"Del Valle L","year":"2002","unstructured":"Del Valle L, Enam S, Lassak A eta]. Insulin-like growth factor I receptor activity in human medulloblastomas. Clin. Cancer Res. 8,1822\u20131830 (2002).","journal-title":"Insulin-like growth factor I receptor activity in human medulloblastomas. Clin. Cancer Res"},{"key":"e_1_2_1_162_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.8418502"},{"key":"e_1_2_1_163_1","first-page":"2218","article-title":"Rubini M et al Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF_i) receptor are nontumorigenic and induce regression of wild type tumors","volume":"54","author":"Resnicoff M","year":"1994","unstructured":"Resnicoff M, Sell C, Rubini M et al Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF_i) receptor are nontumorigenic and induce regression of wild type tumors. Cancer Res. 54,2218\u20132222 (1994).","journal-title":"Cancer Res"},{"key":"e_1_2_1_164_1","doi-asserted-by":"crossref","unstructured":"Wang ZH Ma J Zeng BJ et al. Correlation of glioma cell regression with inhibition of insulin-like growth factor 1 and insulin-like growth factor-binding protein-2 expression. Neuroenclocrinology66 203\u2013211 (1997).","DOI":"10.1159\/000127239"},{"key":"e_1_2_1_165_1","first-page":"2189","article-title":"Flanders AE eta]","volume":"19","author":"Andrews DW","year":"2001","unstructured":"Andrews DW, Resnicoff M, Flanders AE eta]. Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor Type I receptor in malignant astrocytomas. j Clin. Oncol 19, 2189\u20132200 (2001).","journal-title":"Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor Type I receptor in malignant astrocytomas. j Clin. Oncol"},{"key":"e_1_2_1_166_1","doi-asserted-by":"crossref","unstructured":"Bollag G McCormick E Regulators and effectors of ras proteins. Ann. Rev Cell Biol.7 601-632 (1991).Thorough review.","DOI":"10.1146\/annurev.cb.07.110191.003125"},{"key":"e_1_2_1_167_1","doi-asserted-by":"publisher","DOI":"10.1038\/366643a0"},{"key":"e_1_2_1_168_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.62.070193.004223"},{"key":"e_1_2_1_169_1","unstructured":"\u2022\u2022 Detailed review."},{"key":"e_1_2_1_170_1","doi-asserted-by":"crossref","unstructured":"Rowinsky EK Windle JJ Von Hoff DD. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. j Clin. Oncol 17 3631\u20133652 (1999).","DOI":"10.1200\/JCO.1999.17.11.3631"},{"key":"e_1_2_1_171_1","unstructured":"\u2022Thorough overview of Ras biology and famesyl transferase inhibitor (FTI) development."},{"key":"e_1_2_1_172_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/93.14.1062"},{"key":"e_1_2_1_173_1","unstructured":"\u2022Thorough overview of Ras biology and FTI development."},{"key":"e_1_2_1_174_1","first-page":"4682","article-title":"Ras oncogenes in human cancers: a review","volume":"49","author":"Bos JL","year":"1989","unstructured":"Bos JL. Ras oncogenes in human cancers: a review. Cancer Res. 49,4682\u20134689 (1989).","journal-title":"Cancer Res"},{"key":"e_1_2_1_175_1","unstructured":"\u2022\u2022Detailed review of Ras mutations."},{"key":"e_1_2_1_176_1","first-page":"27","article-title":"Kumar S et al Expression of growth factor receptors in human brain tumors","volume":"63","author":"Tuzi NL","year":"1991","unstructured":"Tuzi NL, Venter DJ, Kumar S et al Expression of growth factor receptors in human brain tumors. BE j Cancer 63, 27\u2013233 (1991).","journal-title":"BE j Cancer"},{"key":"e_1_2_1_177_1","first-page":"26","article-title":"Ras activation in astrocytomas and neurofibromas","volume":"25","author":"Guha A","year":"1998","unstructured":"Guha A. Ras activation in astrocytomas and neurofibromas. Can. j Nemo'. Li. 25, 26\u2013281 (1998).","journal-title":"Can. j Nemo'. Li"},{"key":"e_1_2_1_178_1","unstructured":"\u2022Detailed overview of Ras signaling in brain tumors."},{"key":"e_1_2_1_179_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1201455"},{"key":"e_1_2_1_180_1","first-page":"627","article-title":"Feldkamp M etal","volume":"97","author":"Woods SA","year":"2002","unstructured":"Woods SA, Marmor E, Feldkamp M etal. Aberrant G-protein signaling in nervous system tumors. j Neurosurg. 97,627\u2013642 (2002).","journal-title":"Aberrant G-protein signaling in nervous system tumors. j Neurosurg"},{"key":"e_1_2_1_181_1","unstructured":"\u2022\u2022Detailed review."},{"key":"e_1_2_1_182_1","first-page":"3826","article-title":"Shannon P et al Astrocyte-specific expression of activated p21-ras results in malignant formation in a transgenic mouse model of human gliomas","volume":"61","author":"Ding H","year":"2001","unstructured":"Ding H, Roncari L, Shannon P et al Astrocyte-specific expression of activated p21-ras results in malignant formation in a transgenic mouse model of human gliomas. Cancer Res. 61,3826\u20133836 (2001).","journal-title":"Cancer Res"},{"key":"e_1_2_1_183_1","doi-asserted-by":"publisher","DOI":"10.3109\/07357900009023061"},{"key":"e_1_2_1_184_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.9.12.2767"},{"key":"e_1_2_1_185_1","unstructured":"\u2022Thorough review."},{"key":"e_1_2_1_186_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(00)00191-1"},{"key":"e_1_2_1_187_1","first-page":"225","article-title":"Current progress on farnesyl protein transferase inhibitors","volume":"5","author":"Singh SB","year":"2002","unstructured":"Singh SB, Lingham RB. Current progress on farnesyl protein transferase inhibitors. Curr. Opin. Drug Discov. Develop. 5, 225\u2013244 (2002).","journal-title":"Curr. Opin. Drug Discov. Develop"},{"key":"e_1_2_1_188_1","unstructured":"\u2022Comprehensive review of FTIs."},{"key":"e_1_2_1_189_1","first-page":"1685","article-title":"Adjei AA","volume":"38","author":"Haluska P","year":"2002","unstructured":"Haluska P, Dy GK, Adjei AA. Famesyl transferase inhibitors as anticancer agents. Eur.j Cancer38, 1685\u20131700(2002).","journal-title":"Famesyl transferase inhibitors as anticancer agents. Eur.j Cancer"},{"key":"e_1_2_1_190_1","unstructured":"End DW Smets G Todd AV et al. Characterization of the antitumor effects of the selective famesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 61 131-137 (2001)."},{"key":"e_1_2_1_191_1","first-page":"747","article-title":"Buser CA et al Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-1","volume":"1","author":"Lobell RB","year":"2002","unstructured":"Lobell RB, Liu D, Buser CA et al Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-1. Mol Cancer Ther. 1,747\u2013758(2002).","journal-title":"Mol Cancer Ther"},{"key":"e_1_2_1_192_1","first-page":"7514","article-title":"Guha A","volume":"18","author":"Feldkamp MM","year":"1999","unstructured":"Feldkamp MM, Lau N, Guha A. Growth inhibition of astrocytoma cells by famesyl transferase inhibitors is mediated by a combination of antiproliferative, pro-apoptotic and anti-angiogenic effects. Oncogene 18,7514\u20137526 (1999).","journal-title":"Growth inhibition of astrocytoma cells by famesyl transferase inhibitors is mediated by a combination of antiproliferative, pro-apoptotic and anti-angiogenic effects. Oncogene"},{"key":"e_1_2_1_193_1","doi-asserted-by":"crossref","unstructured":"Kurimoto M Hirashima Y Hamada H et al In vitro and in vivo growth inhibition of human malignant astrocytoma cells by the famesyltransferase inhibitor B1620.1 Neurooncol 61 103\u2013112 (2003).","DOI":"10.1023\/A:1022132201313"},{"key":"e_1_2_1_194_1","doi-asserted-by":"crossref","unstructured":"Glass TL Liu TJ Yung WKA. Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor 5CH66336. NeurooncoI2 151\u2013158 (2000).","DOI":"10.1093\/neuonc\/2.3.151"},{"key":"e_1_2_1_195_1","first-page":"4425","article-title":"Isotype-specific Ras-GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status","volume":"61","author":"Feldkamp MM","year":"2001","unstructured":"Feldkamp MM, Lau N, Roncari L, Guha A. Isotype-specific Ras-GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status. Cancer Res. 61,4425\u20134431 (2001).","journal-title":"Cancer Res"},{"key":"e_1_2_1_196_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006123-199911000-00039"},{"key":"e_1_2_1_197_1","first-page":"2761","article-title":"Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells","volume":"20","author":"Bouterfa HL","year":"2000","unstructured":"Bouterfa HL, Sattelmeyer V, Czub S, Vordermark D, Roosen K, Tonn JC. Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells. Anticancer Res. 20, 2761\u20132772 (2000).","journal-title":"Anticancer Res"},{"key":"e_1_2_1_198_1","first-page":"118","article-title":"Guha A","volume":"81","author":"Feldkamp MM","year":"1999","unstructured":"Feldkamp MM, Lau N, Rak J, Kerbel RS, Guha A. Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras. Int.j Cancer81, 118\u2013124 (1999).","journal-title":"Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras. Int.j Cancer"},{"key":"e_1_2_1_199_1","unstructured":"\u2022Demonstrates Ras regulation of vascular endothelial growth factor and angiogenesis."},{"key":"e_1_2_1_200_1","doi-asserted-by":"crossref","unstructured":"Wang W Macaulay RJB. Apoptosis of medulloblastoma cells in vitm follows inhibition of farnesylation using manumycin A. Int.j Cancer82 430\u2013434 (1999).","DOI":"10.1002\/(SICI)1097-0215(19990730)82:3<430::AID-IJC17>3.0.CO;2-9"},{"key":"e_1_2_1_201_1","doi-asserted-by":"crossref","unstructured":"Zujewski J Horak CJ Bol R et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J. Clin. Oncol 18 927\u2013941 (2000).","DOI":"10.1200\/JCO.2000.18.4.927"},{"key":"e_1_2_1_202_1","doi-asserted-by":"crossref","unstructured":"Crul M de Klerk GJ Swart M et al. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J. Clin. Oncol 20 2726\u20132735 (2002).","DOI":"10.1200\/JCO.2002.09.116"},{"key":"e_1_2_1_203_1","unstructured":"Cloughesy T Kuhn J Robins I et al. Phase I trial of R115777 in patients with recurrent malignant glioma taking enzyme inducing anti-epileptic drugs (EIAED). North American Brain Tumor Consortium. Neurooncology3 357 (2001)."},{"key":"e_1_2_1_204_1","unstructured":"Cloughesy T Kuhn J Wen P et al Phase II trial of R115777 (Zamestra) in patients with recurrent glioma not taking enzyme inducing anti-epileptic drugs (EIAED): a North American Brain Tumor Consortium (NABTC) report. Proc. Am. Soc. Clin. Oncol 21 80a (2002)."},{"key":"e_1_2_1_205_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(99)00280-4"},{"key":"e_1_2_1_206_1","unstructured":"\u2022Detailed review of molecular drug discovery"},{"key":"e_1_2_1_207_1","doi-asserted-by":"crossref","unstructured":"Gelman I A Eisenhauer EA Harris AL Ratain MJ Workman P. Anticancer agents targeting signaling molecules and cancer cell environments: challenges for drug development? J. Natl Cancer Inst. 91 1281\u20131287 (1999).","DOI":"10.1093\/jnci\/91.15.1281"},{"key":"e_1_2_1_208_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(01)00785-7"},{"key":"e_1_2_1_209_1","unstructured":"\u2022\u2022Thorough review."},{"key":"e_1_2_1_210_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf648"},{"key":"e_1_2_1_211_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.044"},{"key":"e_1_2_1_212_1","unstructured":"\u2022\u2022 Thorough review."},{"key":"e_1_2_1_213_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.7.1932"},{"key":"e_1_2_1_214_1","first-page":"3165","article-title":"Microarrays as cancer keys: an array of possibilities","volume":"20","author":"Mohr S","year":"2002","unstructured":"Mohr S, Leikauf GD, Keith G, Rihn BH. Microarrays as cancer keys: an array of possibilities. Clin. Oncol 20,3165\u20133175 (2002).","journal-title":"Clin. Oncol"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/14737140.3.5.595","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T15:44:27Z","timestamp":1770911067000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1586\/14737140.3.5.595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10]]},"references-count":210,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2003,10]]}},"alternative-id":["10.1586\/14737140.3.5.595"],"URL":"https:\/\/doi.org\/10.1586\/14737140.3.5.595","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,10]]}}}